
TQB2930 Plus Chemo Drives Responses in Pretreated HER2+ Metastatic Breast Cancer
The novel HER2-targeted bispecific antibody TQB2930 in combination with chemotherapy led to responses and displayed an acceptable safety profile in patients with HER2-positive metastatic breast cancer who received at least 2 prior HER2-targeted therapies, …